Cargando…
A TRPA1 antagonist reverts oxaliplatin-induced neuropathic pain
Neuropathic pain (NeP) is generally considered an intractable problem, which becomes compelling in clinical practice when caused by highly effective chemotherapeutics, such as in the treatment of cancer with oxaliplatin (OXA) and related drugs. In the present work we describe a structurally new comp...
Autores principales: | Nativi, Cristina, Gualdani, Roberta, Dragoni, Elisa, Di Cesare Mannelli, Lorenzo, Sostegni, Silvia, Norcini, Martina, Gabrielli, Gabriele, la Marca, Giancarlo, Richichi, Barbara, Francesconi, Oscar, Moncelli, Maria Rosa, Ghelardini, Carla, Roelens, Stefano |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3684817/ https://www.ncbi.nlm.nih.gov/pubmed/23774285 http://dx.doi.org/10.1038/srep02005 |
Ejemplares similares
-
Injectable liposomal formulations of opiorphin as a new therapeutic strategy in pain management
por: Mennini, Natascia, et al.
Publicado: (2015) -
First-in-Class
Dual Hybrid Carbonic Anhydrase Inhibitors
and Transient Receptor Potential Vanilloid 1 Agonists Revert Oxaliplatin-Induced
Neuropathy
por: Angeli, Andrea, et al.
Publicado: (2023) -
Role of PAR2 in regulating oxaliplatin-induced neuropathic pain via TRPA1
por: Tian, Liujun, et al.
Publicado: (2015) -
Molecular Recognition of Disaccharides in Water: Preorganized Macrocyclic or Adaptive Acyclic?
por: Francesconi, Oscar, et al.
Publicado: (2021) -
A Simple Biomimetic Receptor Selectively Recognizing the GlcNAc(2) Disaccharide in Water
por: Francesconi, Oscar, et al.
Publicado: (2021)